AIM
TVTX icon

Alambic Investment Management’s Travere Therapeutics TVTX Stock Holding History

Alambic Investment Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-26,200
Closed -$496K – 678
2016
Q4 		$496K Sell
26,200
-500
-2% -$10.2K 0.09% 334
2016
Q3 		$598K Buy
26,700
+7,900
+42% +$150K 0.14% 250
2016
Q2 		$335K Buy
18,800
+1,550
+9% +$25.1K 0.08% 360
2016
Q1 		$236K Buy
+17,250
New +$262K 0.08% 371

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Alambic Investment Management's TVTX Position: Q1 2017 in Review

Alambic Investment Management sold out of Travere Therapeutics (TVTX) in Q1 2017, closing a stake of 26,200 shares — an estimated $496K sold.

Alambic Investment Management first reported a position in TVTX in Q1 2016 and held it in 4 quarters. The position peaked at $598K in Q3 2016. 114 funds tracked by Wall St. Rank hold TVTX as of Q1 2017.

  • Alambic Investment Management reported no remaining Travere Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Alambic Investment Management sold 26,200 Travere Therapeutics shares in Q1 2017, an estimated $496K.
  • Alambic Investment Management first reported a position in Travere Therapeutics in Q1 2016 and held it in 4 quarters.
  • Alambic Investment Management's Travere Therapeutics position peaked at $598K in Q3 2016.
  • 114 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2017.

Based on Alambic Investment Management's 13F filing for Q1 2017, filed 9 May 2017.